Novo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion

A day after Madrigal Pharmaceuticals impressed investors, Novo Nordisk is looking to steal the spotlight. The Danish drugmaker reported Friday that semaglutide succeeded in a Phase 3 study of patients with ...